Collateral damage and CRISPR genome editing
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The simplicity and the versatility of clustered regularly interspaced short palindromic repeats/CRISPR-associated protein (CRISPR-Cas) systems have enabled the genetic modification of virtually every organism and offer immense therapeutic potential for the treatment of human disease.Although these systems may function efficiently within eukaryotic cells, there remain concerns about the accuracy of Cas endonuclease effectors and their use for precise gene editing.Recently, two independent reports investigating the editing accuracy of the CRISPR-Cas9 system were published by separate groups at the Wellcome Sanger Institute; our study-Iyer and colleagues [1]-defined the landscape of off-target mutations, whereas the other by Kosicki and colleagues [2] detailed the existence of on-target, potentially deleterious deletions.Although both studies found evidence of large on-target CRISPR-induced deletions, they reached seemingly very different conclusions. So, what do scientists using CRISPR gene-editing technology need to know? Off targets-the need for controlsIyer and colleagues used whole-genome sequencing (WGS) to identify potential off-target damage in mouse embryos and assessed the impact of genomic variation on de novo mutation calls.This study was undertaken in response to Schaefer and colleagues [3]-subsequently retracted-which reported a greater number of mutations at unexpected off-target locations in mice following the delivery of CRISPR reagents in mouse zygotes.Iyer and colleagues emphasised proper experimental controls and use of best practice in the choice of a single-guide RNA (sgRNA) and Cas9-mediated mutagenesis conditions.We demonstrated that if Cas9-mediated mutagenesis were causing off-target mutations, then the rate of these mutations was not distinguishable from the background de novo mutation rate in mouse embryos.The study concluded that efficient CRISPR gene editing was possible without a significant increase in de novo mutation rates, supporting the development of CRISPR-Cas9 as a therapeutic tool.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414
RNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
Kosicki, M., Tomberg, K., & Bradley, A. (2018) · Nature Biotechnology · doi:10.1038/nbt.4192 · Cited by 1,883
Evolved Cas9 variants with broad PAM compatibility and high DNA specificity
Hu, J. H., Miller, S. M., Geurts, M. H., Tang, W., Chen, L., Sun, N., Zeina, C. M., Gao, X., Rees, H. A., Lin, Z., et al. (2018) · Nature · doi:10.1038/nature26155 · Cited by 1,552
Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014) · eLife · doi:10.7554/elife.04766 · Cited by 1,189
CIRCLE-Seq: A highly sensitive in vitro screen for genome-wide CRISPR-cas9 nuclease off-targets
Tsai, S. Q., Nguyen, N. T., Malagon-Lopez, J., Topkar, V. V., Aryee, M. J., & Joung, J. K. (2017) · Nature Methods · doi:10.1038/nmeth.4278 · Cited by 814
Directed evolution of CRISPR-Cas9 to increase its specificity
Lee, J. K., Jeong, E., Lee, J., Jung, M., Shin, E., Kim, Y.-H., Lee, K., Jung, I., Kim, D., Kim, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05477-x · Cited by 525
Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing
Amabile, A., Migliara, A., Capasso, P., Biffi, M., Cittaro, D., Naldini, L., & Lombardo, A. (2016) · Cell · doi:10.1016/j.cell.2016.09.006 · Cited by 516
Large deletions induced by Cas9 cleavage
Adikusuma, F., Piltz, S., Corbett, M. A., Turvey, M., McColl, S. R., Helbig, K. J., Beard, M. R., Hughes, J., Pomerantz, R. T., & Thomas, P. Q. (2018) · Nature · doi:10.1038/s41586-018-0380-z · Cited by 371
Cited by
Microhomologies are prevalent at Cas9-induced larger deletions
Owens, D. D. G., Caulder, A., Frontera, V., Harman, J. R., Allan, A. J., Bucakci, A., Greder, L., Codner, G. F., Hublitz, P., McHugh, P. J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz459 · Cited by 136
“A recent study also found that LDs >250 bp occurred in up to 20% of alleles (17,64) (Figure 6K).”
BackgroundDetection of Deleterious On-Target Effects after HDR-Mediated CRISPR Editing
Weisheit, I., Kroeger, J. A., Malik, R., Klimmt, J., Crusius, D., Dannert, A., Dichgans, M., & Paquet, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107689 · Cited by 125
Genetic Variation and Unintended Risk in the Context of Old and New Breeding Techniques
Singer, S. D., Laurie, J. D., Bilichak, A., Kumar, S., & Singh, J. (2021) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2021.1883826 · Cited by 77
“Furthermore, similar findings have not been corroborated in animal systems subsequently (Iyer et al., 2018; Dong et al., 2019; Thomas et al., 2019).”
Result
Metadata
- Authors
- Thomas, M., Burgio, G., Adams, D. J., & Iyer, V.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-03-14
- Volume
- 15
- Issue
- 3
- Pages
- e1007994
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- OpenAlex
- W2922243354
- Cited by
- 38
- References
- 10
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.